Univest
Univest
  • Markets

Shilpa Medicare Share Price Forecast to 2030

  • July 27, 2026
  • Posted by: Kashish Aggarwal
  • Category: News
No Comments
Shilpa Medicare Share Price Forecast to 2030

Shilpa Medicare share price Rs 621.80. 52W high Rs 650.00, low Rs 260.00. Market cap Rs 12164Cr. Cr. 2030 scenario range Rs 466.35 to Rs 1,119.

Shilpa Medicare manufactures oncology APIs and formulations for global pharma companies, with a growing finished dosage form business. As a listed player in the Pharmaceuticals segment, the Shilpa Medicare share price trajectory over the next three years will be shaped by rising global demand for oncology APIs and complex generic formulations.

Table of Contents

Toggle
  • Shilpa Medicare Share Price Today and Key Metrics
  • Key Factors Driving Shilpa Medicare Share Price
  • Risk Factors That Could Weigh on Shilpa Medicare Share Price
  • Shilpa Medicare Share Price Forecast: 3-Year Scenarios
  • How to Track Shilpa Medicare Share Price
  • Investor Considerations for Shilpa Medicare
  • Shilpa Medicare Share Price: Fundamental Analysis and Outlook
  • Frequently Asked Questions: Shilpa Medicare Share Price
    • What is Shilpa Medicare’s share price today?
    • What is the Shilpa Medicare share price forecast for the next 3 years?
    • Is Shilpa Medicare a good long-term investment?
    • What factors drive Shilpa Medicare share price?
    • What are the risks of investing in Shilpa Medicare?
    • What is Shilpa Medicare’s P/E ratio?
    • How does Shilpa Medicare compare to its peers?

Shilpa Medicare Share Price Today and Key Metrics

Metric Value
Current Price (Live) ₹621.80
52-Week High / Low ₹650 – ₹260
Market Cap ₹ 12,164 Cr.
P/E Ratio 52.1
Book Value ₹ 132
ROE 9.40 %
ROCE 11.0 %
Dividend Yield 0.08 %

Shilpa Medicare is currently trading at ₹621.80 with a 52-week range of ₹650 – ₹260. The current P/E ratio of 52.1 provides a baseline for valuation comparison with peers in the Pharmaceuticals space.

Log in to Univest to access stock insights and portfolio tracking for Shilpa Medicare.

Key Factors Driving Shilpa Medicare Share Price

The primary growth catalyst for Shilpa Medicare is rising global demand for oncology APIs and complex generic formulations. This driver is anchored in structural trends within the Pharmaceuticals sector, which remains a focus area for domestic institutional investors tracking India’s economic growth story.

Sector peers including Divi’s Laboratories, Neuland Laboratories, NGL Fine-Chem operate in similar addressable markets and provide useful benchmarks for valuation and growth trajectories. Monitoring these peers alongside Shilpa Medicare’s own quarterly disclosures offers a more complete picture of the competitive landscape and the factors likely to move the Shilpa Medicare share price.

Risk Factors That Could Weigh on Shilpa Medicare Share Price

Investors in Shilpa Medicare must account for the following: oncology API pricing faces competitive pressure and regulatory compliance for cytotoxic manufacturing is stringent. These risks are not unique to Shilpa Medicare and affect the broader Pharmaceuticals segment, but the degree to which they impact the Shilpa Medicare share price depends on its balance sheet strength, client diversification, and management execution track record.

Shilpa Medicare Share Price Forecast: 3-Year Scenarios

The following indicative scenario analysis is illustrative only and does not constitute a research-grade price target. Actual outcomes will depend on company performance, sector dynamics, and macroeconomic conditions.

Scenario 3-Year Indicative Range Key Assumptions
Bull Case ₹1,119 Strong execution, sector tailwinds materialise, margin expansion
Base Case ₹839.43 Steady growth in line with sector, manageable cost pressures
Bear Case ₹466.35 Demand slowdown, margin compression, sector headwinds materialise

These ranges are illustrative only and do not constitute investment advice. The bull case assumes growth drivers materialise fully, the bear case reflects meaningful headwinds, and the base case represents a moderate sector-average outcome.

Consult a SEBI-registered investment adviser before making any investment decisions in this stock.

How to Track Shilpa Medicare Share Price

Tracking the Shilpa Medicare share price over a multi-year horizon requires monitoring both company-specific and sector-level indicators. Key metrics that influence share price in the Pharmaceuticals segment include revenue growth, EBITDA margin, return on capital employed, and debt profile. The Shilpa Medicare share price at ₹621.80 should be evaluated alongside its P/E ratio, book value, and dividend yield relative to peers.

The 52-week range of ₹650 – ₹260 for the Shilpa Medicare share price reflects the band within which it has traded over the past year. Comparing the Shilpa Medicare share price trajectory with the Pharmaceuticals index and peers such as Divi’s Laboratories, Neuland Laboratories helps contextualise whether moves are company-specific or sector-driven.

Retail investors monitoring the Shilpa Medicare share price should also track NSE filings, annual reports, and quarterly investor presentations for the most reliable picture of business direction and management guidance.

Investor Considerations for Shilpa Medicare

Before investing in Shilpa Medicare, evaluate the company’s competitive positioning in the Pharmaceuticals segment, the balance sheet quality, and management guidance on growth and margins in recent communications. The Pharmaceuticals index provides a sector benchmark to assess relative share price performance on a risk-adjusted basis. Retail investors are advised to use multiple data sources and consult a SEBI-registered adviser before forming an investment view.

Download the Univest app for real-time stock data, research, and portfolio management.

Shilpa Medicare Share Price: Fundamental Analysis and Outlook

A comprehensive assessment of the Shilpa Medicare share price over a three-year horizon must go beyond current metrics to consider the broader industry dynamics. The Pharmaceuticals sector in India has seen significant structural evolution, driven by government policy, domestic demand growth, and global supply chain realignment. Companies like Shilpa Medicare that are positioned in the right part of this structural shift tend to see their share prices reflect improving earnings visibility over time.

For the Shilpa Medicare share price to sustain an upward trajectory, the company needs to consistently demonstrate revenue growth, margin stability, and efficient capital allocation. Quarterly EBITDA margins and return on equity are leading indicators that institutional investors track closely when assessing share price momentum in the Pharmaceuticals segment.

The share price of any listed company also reflects sentiment-driven factors including sector rotation, FII and DII flows, and macro variables such as interest rates and currency movements. Investors monitoring the Shilpa Medicare share price should factor in both the fundamental business trajectory and these broader market variables to form a balanced view of the 3-year outlook.

Frequently Asked Questions: Shilpa Medicare Share Price

What is Shilpa Medicare’s share price today?

Shilpa Medicare (SHILPAMED) is currently trading at ₹621.80 with a 52-week range of ₹650 – ₹260. For real-time prices, check the Univest app or NSE website.

What is the Shilpa Medicare share price forecast for the next 3 years?

The Shilpa Medicare share price outlook over the next three years hinges on rising global demand for oncology APIs and complex generic formulations. Investors should track quarterly results and consult a SEBI-registered adviser for personalised guidance.

Is Shilpa Medicare a good long-term investment?

Shilpa Medicare operates in the Pharmaceuticals sector. Long-term investment decisions should be based on the company’s fundamentals, competitive positioning, and your individual risk profile.

What factors drive Shilpa Medicare share price?

Key drivers include rising global demand for oncology APIs and complex generic formulations, quarterly earnings, sector trends in Pharmaceuticals, and broader market conditions.

What are the risks of investing in Shilpa Medicare?

Key risks include oncology API pricing faces competitive pressure and regulatory compliance for cytotoxic manufacturing is stringent. Equity investments carry market risk and past performance is no guarantee of future results.

What is Shilpa Medicare’s P/E ratio?

Shilpa Medicare’s current P/E ratio is 52.1. Compare this with Pharmaceuticals peers before making any investment decision.

How does Shilpa Medicare compare to its peers?

Shilpa Medicare competes with Divi’s Laboratories, Neuland Laboratories in the Pharmaceuticals segment. Comparing revenue growth, margins and valuations across peers aids in relative assessment.

Disclaimer: This article is for educational and informational purposes only and does not constitute financial advice. Investing in equities involves risk. Please consult a SEBI-registered research analyst or investment adviser before making investment decisions. Research Analyst: SEBI Registration No. INH000013776. Investment Adviser: INA000017639. Stock Broker: INZ000317437.



Author: Kashish Aggarwal
Kashish Aggarwal is a Financial Content Writer at Univest, covering Indian equity markets with a focus on share price target frameworks, technical analysis education, and sector deep-dives. Her published work spans bull-case/bear-case share price analysis, event-driven stock reactions, and beginner-friendly educational guides. Her articles blend fundamental analysis (analyst consensus targets, P/E, loan book quality, margin dynamics) with technical analysis (moving averages, 200-DMA, support/resistance levels) — giving retail investors a complete framework before any position. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards. Coverage Areas • Share price targets — REC Ltd, Adani Green Energy (bull/bear case frameworks) • Event-driven analysis — Redington (US tariff impact), Star Cement (technical breakdown) • Technical analysis education — Direct Market Access, 200-DMA, indicator interpretation • Thematic listicles — Highest Dividend Paying Stocks, Real Estate Penny Stocks, Intraday Picks • Sector coverage — IT distribution, renewable energy, infrastructure finance, cement, real estate

Leave a Reply Cancel reply